Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients

Timothy R. Aksamit; Nicholas Locantore; Doreen Addrizzo-Harris; Juzar Ali; Alan Barker; Ashwin Basavaraj; Megan Behrman; Amanda E. Brunton; Sarah Chalmers; Radmila Choate; Nathan C. Dean; Angela DiMango; David Fraulino; Margaret M. Johnson; Nicole C. Lapinel; Diego J. Maselli; Pamela J. McShane; Mark L. Metersky; Bruce E. Miller; Edward T. Naureckas; Anne E. O’Donnell; Kenneth N. Olivier; Elly Prusinowski; Marcos I. Restrepo; Christopher J. Richards; Gloria Rhyne; Andreas Schmid; George M. Solomon; Ruth Tal-Singer; Byron Thomashow; Gregory Tino; Kevin Tsui; Sumith Abraham Varghese; Heather E. Warren; Kevin Winthrop; Beth Shoshanna Zha

doi:10.1164/rccm.202307-1165OC

Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients

Timothy R. Aksamit
, Nicholas Locantore
, Doreen Addrizzo-Harris
, Juzar Ali
, Alan Barker
, Ashwin Basavaraj
, Megan Behrman
, Amanda E. Brunton
, Sarah Chalmers
, Radmila Choate
, Nathan C. Dean
, Angela DiMango
, David Fraulino
, Margaret M. Johnson
, Nicole C. Lapinel
, Diego J. Maselli
, Pamela J. McShane
, Mark L. Metersky
, Bruce E. Miller
, Edward T. Naureckas

Anne E. O’Donnell, Kenneth N. Olivier, Elly Prusinowski, Marcos I. Restrepo, Christopher J. Richards, Gloria Rhyne, Andreas Schmid, George M. Solomon, Ruth Tal-Singer, Byron Thomashow, Gregory Tino, Kevin Tsui, Sumith Abraham Varghese, Heather E. Warren, Kevin Winthrop, Beth Shoshanna Zha

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Rationale: Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives: To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods: Patients in the Bronchiectasis and NTM Research Registry with >5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log rank test. Measurements and Main Results: In total, 2,634 patients wer included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV₁ percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P, 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4% and 3% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P, 0.05). Conclusions: Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.

Original language	English
Pages (from-to)	108-118
Number of pages	11
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	210
Issue number	1
DOIs	https://doi.org/10.1164/rccm.202307-1165OC
State	Published - Jul 1 2024

Bibliographical note

Publisher Copyright:
Copyright © 2024 by the American Thoracic Society.

Funding

Supported by a research grant from Insmed. The Bronchiectasis and NTM Research Registry is funded by the Richard H. Scarborough Bronchiectasis Research Fund, the Anna-Maria and Stephen Kellen Foundation, and the Bronchiectasis and NTM Industry Advisory Committee. Supported by a research grant from Insmed. The Bronchiectasis and NTM Research Registry is funded by the Richard H. Scarborough Bronchiectasis Research Fund, the Anna-Maria and Stephen Kellen Foundation, and the Bronchiectasis and NTM Industry Advisory Committee. The authors acknowledge the COPD Foundation, a 501(c)(3) nonprofit organization, which manages the Bronchiectasis and NTM Research Registry. The registry is funded by the Richard H. Scarborough Bronchiectasis Research Fund, the Anna-Maria and Stephen Kellen Foundation, a research grant from Insmed Incorporated, and the Bronchiectasis and NTM Industry Advisory Committee. It should also be noted that this work would not have been possible without the comprehensive chart reviews and recording of data by the dedicated research coordinators and principal investigators at each of the participating registry sites. Medical writing services were provided by John Glossop and James Glossop of Final Copy Ltd.

Funders
Richard H. Scarborough Bronchiectasis Research Fund
Anna-Maria and Stephen Kellen Foundation
COPD Foundation
John Glossop and James Glossop of Final Copy Ltd

Keywords

Pseudomonas aeruginosa
exacerbation
hospitalization
mortality
spirometry

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine

Access to Document

10.1164/rccm.202307-1165OC

Cite this

Aksamit, T. R., Locantore, N., Addrizzo-Harris, D., Ali, J., Barker, A., Basavaraj, A., Behrman, M., Brunton, A. E., Chalmers, S., Choate, R., Dean, N. C., DiMango, A., Fraulino, D., Johnson, M. M., Lapinel, N. C., Maselli, D. J., McShane, P. J., Metersky, M. L., Miller, B. E., ... Zha, B. S. (2024). Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients. American Journal of Respiratory and Critical Care Medicine, 210(1), 108-118. https://doi.org/10.1164/rccm.202307-1165OC

@article{b3610d4fc0d547cda5046d5b918528e0,

title = "Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients",

abstract = "Rationale: Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives: To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods: Patients in the Bronchiectasis and NTM Research Registry with >5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log rank test. Measurements and Main Results: In total, 2,634 patients wer included: 1,549 (58.8\%) with and 1,085 (41.2\%) without NTM at baseline. All-cause mortality (95\% confidence interval) at Year 5 was 12.1\% (10.5\%, 13.7\%) overall, 12.6\% (10.5\%, 14.8\%) in patients with NTM, and 11.5\% (9.0\%, 13.9\%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV1 percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P, 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4\% and 3\% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P, 0.05). Conclusions: Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.",

keywords = "Pseudomonas aeruginosa, exacerbation, hospitalization, mortality, spirometry",

author = "Aksamit, \{Timothy R.\} and Nicholas Locantore and Doreen Addrizzo-Harris and Juzar Ali and Alan Barker and Ashwin Basavaraj and Megan Behrman and Brunton, \{Amanda E.\} and Sarah Chalmers and Radmila Choate and Dean, \{Nathan C.\} and Angela DiMango and David Fraulino and Johnson, \{Margaret M.\} and Lapinel, \{Nicole C.\} and Maselli, \{Diego J.\} and McShane, \{Pamela J.\} and Metersky, \{Mark L.\} and Miller, \{Bruce E.\} and Naureckas, \{Edward T.\} and O{\textquoteright}Donnell, \{Anne E.\} and Olivier, \{Kenneth N.\} and Elly Prusinowski and Restrepo, \{Marcos I.\} and Richards, \{Christopher J.\} and Gloria Rhyne and Andreas Schmid and Solomon, \{George M.\} and Ruth Tal-Singer and Byron Thomashow and Gregory Tino and Kevin Tsui and Varghese, \{Sumith Abraham\} and Warren, \{Heather E.\} and Kevin Winthrop and Zha, \{Beth Shoshanna\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2024 by the American Thoracic Society.",

year = "2024",

month = jul,

day = "1",

doi = "10.1164/rccm.202307-1165OC",

language = "English",

volume = "210",

pages = "108--118",

number = "1",

}

Aksamit, TR, Locantore, N, Addrizzo-Harris, D, Ali, J, Barker, A, Basavaraj, A, Behrman, M, Brunton, AE, Chalmers, S, Choate, R, Dean, NC, DiMango, A, Fraulino, D, Johnson, MM, Lapinel, NC, Maselli, DJ, McShane, PJ, Metersky, ML, Miller, BE, Naureckas, ET, O’Donnell, AE, Olivier, KN, Prusinowski, E, Restrepo, MI, Richards, CJ, Rhyne, G, Schmid, A, Solomon, GM, Tal-Singer, R, Thomashow, B, Tino, G, Tsui, K, Varghese, SA, Warren, HE, Winthrop, K & Zha, BS 2024, 'Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients', American Journal of Respiratory and Critical Care Medicine, vol. 210, no. 1, pp. 108-118. https://doi.org/10.1164/rccm.202307-1165OC

TY - JOUR

T1 - Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients

AU - Aksamit, Timothy R.

AU - Locantore, Nicholas

AU - Addrizzo-Harris, Doreen

AU - Ali, Juzar

AU - Barker, Alan

AU - Basavaraj, Ashwin

AU - Behrman, Megan

AU - Brunton, Amanda E.

AU - Chalmers, Sarah

AU - Choate, Radmila

AU - Dean, Nathan C.

AU - DiMango, Angela

AU - Fraulino, David

AU - Johnson, Margaret M.

AU - Lapinel, Nicole C.

AU - Maselli, Diego J.

AU - McShane, Pamela J.

AU - Metersky, Mark L.

AU - Miller, Bruce E.

AU - Naureckas, Edward T.

AU - O’Donnell, Anne E.

AU - Olivier, Kenneth N.

AU - Prusinowski, Elly

AU - Restrepo, Marcos I.

AU - Richards, Christopher J.

AU - Rhyne, Gloria

AU - Schmid, Andreas

AU - Solomon, George M.

AU - Tal-Singer, Ruth

AU - Thomashow, Byron

AU - Tino, Gregory

AU - Tsui, Kevin

AU - Varghese, Sumith Abraham

AU - Warren, Heather E.

AU - Winthrop, Kevin

AU - Zha, Beth Shoshanna

PY - 2024/7/1

Y1 - 2024/7/1

N2 - Rationale: Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives: To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods: Patients in the Bronchiectasis and NTM Research Registry with >5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log rank test. Measurements and Main Results: In total, 2,634 patients wer included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV1 percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P, 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4% and 3% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P, 0.05). Conclusions: Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.

AB - Rationale: Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives: To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods: Patients in the Bronchiectasis and NTM Research Registry with >5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log rank test. Measurements and Main Results: In total, 2,634 patients wer included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV1 percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P, 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4% and 3% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P, 0.05). Conclusions: Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.

KW - Pseudomonas aeruginosa

KW - exacerbation

KW - hospitalization

KW - mortality

KW - spirometry

UR - https://www.scopus.com/pages/publications/85197961717

UR - https://www.scopus.com/pages/publications/85197961717#tab=citedBy

U2 - 10.1164/rccm.202307-1165OC

DO - 10.1164/rccm.202307-1165OC

M3 - Article

C2 - 38668710

AN - SCOPUS:85197961717

SN - 1073-449X

VL - 210

SP - 108

EP - 118

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

IS - 1

ER -

Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this